MX2021015418A - Terapia inmunooncologica. - Google Patents

Terapia inmunooncologica.

Info

Publication number
MX2021015418A
MX2021015418A MX2021015418A MX2021015418A MX2021015418A MX 2021015418 A MX2021015418 A MX 2021015418A MX 2021015418 A MX2021015418 A MX 2021015418A MX 2021015418 A MX2021015418 A MX 2021015418A MX 2021015418 A MX2021015418 A MX 2021015418A
Authority
MX
Mexico
Prior art keywords
immuno
isoflavone compounds
oncology therapy
oncology
therapy
Prior art date
Application number
MX2021015418A
Other languages
English (en)
Inventor
Graham Kelly
Olivier Laczka
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902518A external-priority patent/AU2019902518A0/en
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of MX2021015418A publication Critical patent/MX2021015418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para mejorar una respuesta en un individuo a la terapia inmunooncológica del cáncer.
MX2021015418A 2019-07-17 2020-07-16 Terapia inmunooncologica. MX2021015418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019902518A AU2019902518A0 (en) 2019-07-17 Immuno-oncology therapy
PCT/AU2020/050730 WO2021007618A1 (en) 2019-07-17 2020-07-16 Immuno-oncology therapy using isoflavone compounds

Publications (1)

Publication Number Publication Date
MX2021015418A true MX2021015418A (es) 2022-04-12

Family

ID=74209595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015418A MX2021015418A (es) 2019-07-17 2020-07-16 Terapia inmunooncologica.

Country Status (11)

Country Link
US (1) US20210275493A1 (es)
EP (1) EP3999052A4 (es)
JP (1) JP2022541218A (es)
KR (1) KR20220035038A (es)
CN (1) CN114072140A (es)
AU (1) AU2020313090A1 (es)
BR (1) BR112021026559A2 (es)
CA (1) CA3139314A1 (es)
IL (1) IL289708A (es)
MX (1) MX2021015418A (es)
WO (1) WO2021007618A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
US20070196381A1 (en) * 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
CN102215841A (zh) * 2008-08-29 2011-10-12 诺沃根研究控股有限公司 免疫调节活性
EP2561079A1 (en) * 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
DK3183254T3 (da) * 2014-08-21 2019-08-19 Boehringer Ingelheim Int Nye spiro[3h-indol-3,2 ?-pyrrolidin]-2(1h)-one forbindelser og derivater som mdm2-p53 inhibitorer
CN106955354B (zh) * 2016-01-11 2020-06-19 中国科学院分子细胞科学卓越创新中心 用于肿瘤免疫治疗的联合用药物组合
US11559510B2 (en) * 2016-04-06 2023-01-24 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
US20210060158A1 (en) * 2017-09-19 2021-03-04 Institut Curie Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
WO2019240871A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
JP2021535187A (ja) * 2018-06-15 2021-12-16 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｓ−エクオールを用いた黒色腫の処置及び予防方法
WO2020102325A1 (en) * 2018-11-13 2020-05-22 Yee Amy Compositions and methods of enhancing immunotherapies

Also Published As

Publication number Publication date
BR112021026559A2 (pt) 2022-02-15
IL289708A (en) 2022-03-01
KR20220035038A (ko) 2022-03-21
US20210275493A1 (en) 2021-09-09
JP2022541218A (ja) 2022-09-22
AU2020313090A1 (en) 2021-12-23
EP3999052A1 (en) 2022-05-25
EP3999052A4 (en) 2023-08-09
WO2021007618A1 (en) 2021-01-21
CA3139314A1 (en) 2021-01-21
CN114072140A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
CL2022001731A1 (es) Inhibidores de egfr.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
MX2021013531A (es) Inhibidores de cdk.
MX2016004742A (es) Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.
BR112021025491A2 (pt) Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
BR112013020975A2 (pt) compostos contendo fósforo como inibidores de proteína quinases
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2017001459A (es) Sintesis de fosforamidatos.
PH12017501880A1 (en) Methods for treating cancer
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
MX2022001167A (es) Metodo para el tratamiento de una composicion que comprende vainillina natural.
MX2021015418A (es) Terapia inmunooncologica.
BR112013024361A2 (pt) novos compostos de azaspirodecanona como inibidores de hsl
MX2023007554A (es) Compuesto espirocíclico como inhibidor del homólogo del oncogén viral del sarcoma 2 de rata de kirsten con mutación g12c (kras-g12c).
UY39832A (es) Inhibidores de cdk2
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.